Abstract
BackgroundSignificantly more DECIDE patients receiving subcutaneous daclizumab HYP (daclizumab) 150 mg achieved no evidence of disease activity (NEDA) vs intramuscular interferon beta-1a (IFNβ1a) 30 µg over 96 weeks. Early residual...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Neurology, Neurosurgery & Psychiatry
Paper Title
Journal
Date
